FDA approves obesity drug that helped people cut weight 15%


Regulators say a new version of a popular diabetes medicine can be sold as a weight-loss drug in the U.S.

The Food and Drug Administration on Friday approved Wegovy.

It’s a higher-dose version of a diabetes drug from the Danish company Novo Nordisk. In company-funded studies, participants taking Wegovy had average weight loss of 15%.

Participants lost weight steadily for 14 months before plateauing. In a comparison group getting dummy shots, the average weight loss was about 2.5%.

More than 100 million adults in the U.S. are obese.

Like other weight-loss drugs, it’s supposed to be used along with exercise and a healthy diet.


Top Local Stories